Barclays Raises TMO Price Target to $775

Barclays maintained its Overweight rating on Thermo Fisher Scientific Inc. TMO on October 22, 2026, while raising its price target from $750.00 to $775.00. Research notes from the firm detail a continued positive outlook for the healthcare equipment and services provider based on its market position. Shares closed at $676.63 on the day of the announcement.

TMO Thermo Fisher Scientific Inc.

$694.02 ▲ +17.46% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Barclays's Call on Thermo Fisher Scientific Inc.

The research note issued on October 22, 2026, reflects the firm's forward-looking confidence in the business, moving the target higher from the previous $750.00 level to $775.00 while keeping the Overweight rating in place. Several other research firms also updated their outlooks on the same day. RBC Capital maintained a Sector Perform rating and adjusted its target from $580.00 to $730.00. TD Cowen kept a Buy rating and lifted its target from $760.00 to $810.00. Stifel held a Buy rating while moving its target from $650.00 to $775.00, and Baird kept an Outperform rating with a target shift from $723.00 to $756.00. Across the broader analyst community, the stock carries a consensus recommendation of strong buy with a mean price target of $706.69 based on 26 analyst opinions.

Other Institutional Activity in Thermo Fisher Scientific Inc.

Franklin Resources, Inc. grew its holdings by 458,515 shares, ending with 7,271,514 shares worth about $4,920,124,553 in its report filed for the period ending June 30, 2026. This marked a 6.7% increase for the fund's position.

Thermo Fisher Scientific Inc. Stock Up 1.0%

The stock recently traded around $694.02 as of October 22, 2026, up about 2.6% since closing at $676.63 on the date of the analyst updates. Shares trade above both their 50-day moving average of $641.93 and their 200-day moving average of $548.71.

Recent Earnings

The company generated trailing twelve month revenue of $47.35 billion with earnings of $18.96 per share. The company reported a net profit margin of 14.9% and a return on equity of 13.4%. Its next earnings report is scheduled for January 28, 2027.

Dividend

The company pays an annual dividend rate of $1.88 per share, which translates to a dividend yield of 0.27% based on current trading levels. The payout ratio sits at 9.7% of earnings.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Company insiders completed several share sales over the summer months. On August 19, 2026, officer Lisa P. Britt sold 11,440 shares at an average price of $613.12 for a total of $7,014,093. Chief executive officer Marc N. Casper sold 20,000 shares on August 21, 2026, valued at $12,561,823, followed by a smaller sale of 275 shares on August 24, 2026, worth $172,439. Later, on August 31, 2026, president Gianluca Pettiti sold 4,133 shares at an average price of $614.38 for a total of $2,539,233. None of these transactions were reported as part of a Rule 10b5-1 trading plan.

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. operates from Waltham, Massachusetts, providing life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products to customers globally. The firm supports research, clinical diagnostics, and pharmaceutical development across four core operating segments.

Bottom Line

Investors will watch how the stock performs relative to the new $775.00 target ahead of the company's next earnings release on January 28, 2027. Analyst ratings represent forward-looking opinions and do not guarantee future stock price movements.